Replies to post #182343 on Biotech Values

[DewDiligence]

PTLA sells 7.1M* shares @$26.00, an 11% discount to yesterday’s closing price:

http://finance.yahoo.com/news/portola-announces-pricing-public-offering-231146856.html

*Assuming exercise of underwriter’s option.

[DewDiligence]

PTLA’s Annexa-A* hits primary endpoint in Phase-3 Xarelto-reversal trial:

http://finance.yahoo.com/news/portola-announces-phase-3-annexa-130000275.html

A similar phase-3 trial succeeded in Eliquis-reversal (#msg-106808552); however, I remain somewhat skeptical about the FDA regulatory pathway (#msg-99274632).

*F/k/a Andexanet alfa / PRT4445.

[DewDiligence]

PTLA reports more Annexa-A* data from phase-3 Eliquis-reversal trial:

http://finance.yahoo.com/news/portola-pharmaceuticals-announces-topline-data-120000038.html

*F/k/a Andexanet alfa, PRT4445.